The present invention creates drugs that are both zinc carriers and ionophores, thus capable of delivering zinc intracellularly and in so doing inhibiting COVlD-19 infection. The drug inventions further attack SARS sequelae of COV1D19 infection, such as development of bacterial pneumonias, most prevalent in the elderly, which are attributable to intrapulmonary zinc deficiency. As such, they could be important primary therapies for SARS. The zinc/ionophore porters can be delivered alone, or upon coupling to other antivirals.
展开▼
